Literature DB >> 24107927

Response to "A case of 5-FU-related severe toxicity associated with the P.Y186C DPYD variant".

S M Offer1, R B Diasio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24107927      PMCID： PMC4112558          DOI： 10.1038/clpt.2013.207

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

1.  A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant.

Authors:  A Zaanan; L-M Dumont; M-A Loriot; J Taieb; C Narjoz
Journal:  Clin Pharmacol Ther       Date:  2013-09-13       Impact factor: 6.875

2.  A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.

Authors:  M Wasif Saif; Adam M Lee; Steven M Offer; Kathleen McConnell; Valerie Relias; Robert B Diasio
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

3.  Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Authors:  Steven M Offer; Natalie J Wegner; Croix Fossum; Kangsheng Wang; Robert B Diasio
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

4.  Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Authors:  K E Caudle; C F Thorn; T E Klein; J J Swen; H L McLeod; R B Diasio; M Schwab
Journal:  Clin Pharmacol Ther       Date:  2013-08-29       Impact factor: 6.875

5.  A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.

Authors:  S M Offer; A M Lee; L K Mattison; C Fossum; N J Wegner; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2013-04-03       Impact factor: 6.875
  5 in total
  4 in total

Review 1.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

2.  Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.

Authors:  Rentian Wu; Qian Nie; Erin E Tapper; Calvin R Jerde; Garrett S Dunlap; Shikshya Shrestha; Tarig A Elraiyah; Steven M Offer; Robert B Diasio
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

3.  Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

Authors:  Steven M Offer; Croix C Fossum; Natalie J Wegner; Alexander J Stuflesser; Gabriel L Butterfield; Robert B Diasio
Journal:  Cancer Res       Date:  2014-03-19       Impact factor: 12.701

Review 4.  Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.

Authors:  Robert B Diasio; Steven M Offer
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.